lol, even the pup_puta/dungforbrains impostor is as much an idiot as the original. i guess expecting more for a nickel a throw is a bit preposterous...
ymbacc • Jul 1, 2015 11:11 PM Flag
1users liked this postsusers disliked this posts0Reply
Like the 1st of every month.
Don't be surprised if you a see a Form 4 filed tomorrow after hours. Larson will have sold some shares today according to his trading plan.
According to the plan, these sales will keep happening throughout Dec 2015 and they're for 12.5% of his position. It's not like he's selling out. Please see below quoted directly from the SEC filing taken from the 8K filed on March 19th.
"Pursuant to the terms of the Plan, Mr. Larson's brokers may sell up to 120,000 shares of the Company's common stock ("Common Stock") held by Mr. Larson, including Common Stock to be acquired upon the exercise of stock options. Mr. Larson is entering the Plan in part to satisfy tax obligations resulting from the exercise of previously granted stock options, but also for longer term diversification purposes. The shares that may be sold under the Plan represent approximately 12.5% of Mr. Larson's equity holdings in the Company as of February 28, 2015 (including vested and unvested stock options). The Plan will commence on April 1, 2015 and end on December 31, 2015, and sales will be made ratably over that period."
markets in the U.S. CLOSED pup_puta, another wasted bash by this mb`s preeminent moron(not to worry pat as that you`re in the top 3).....but still entertaining as ever!
2015 Market Holidays and Half-Days
NYSE NASDAQ SIFMA (Bond Market)*
New Year's Eve -- December 31, 2014 OPEN OPEN REC. 2:00 P.M. CLOSE
New Year's Day -- January 1, 2015 CLOSED CLOSED REC. CLOSE
Martin Luther King Jr. Day -- January 19, 2015 CLOSED CLOSED REC. CLOSE
Washington's Birthday -- February 16, 2015 CLOSED CLOSED REC. CLOSE
Thursday -- April 2, 2015 OPEN OPEN OPEN
Good Friday -- April 3, 2015 CLOSED CLOSED REC. 12 P.M. CLOSE
Friday -- May 22, 2015 OPEN OPEN REC. 2:00 P.M. CLOSE
Memorial Day -- May 25, 2015 CLOSED CLOSED REC. CLOSE
Friday -- July 3, 2015 CLOSED CLOSED REC. CLOSE
Saturday -- Independence Day -- July 4, 2015 CLOSED CLOSED REC. CLOSE
Labor Day -- September 7, 2015 CLOSED CLOSED REC. CLOSE
Columbus Day -- October 12, 2015 OPEN OPEN REC. CLOSE
Veteran's Day -- November 11, 2015 OPEN OPEN REC. CLOSE
Thanksgiving Day -- November 26, 2015 CLOSED CLOSED REC. CLOSE
Friday -- November 27, 2015 OPEN TIL 1:00 P.M. OPEN TIL 1:00 P.M. REC. 2:00 P.M. CLOSE
Christmas Eve Day -- December 24, 2015 OPEN TIL 1:00 P.M. OPEN TIL 1:00 P.M. REC. 2:00 P.M. CLOSE
Christmas Day -- December 25, 2015 CLOSED CLOSED REC. CLOSE
New Year's Eve Day -- December 31, 2015 OPEN OPEN REC. 2:00 P.M. CLOSE
New Year's Day -- January 1, 2016 CLOSED CLOSED REC. CLOSE
budrocky, you and any other long that also finds this link to be useful is indeed welcome!
so that's how it's done in/at the Manila dump where you reside and reign as "Lord of the Flies"? as usual mumbo jumbo that only you may parlay, priceless!
no suprise pup_puta that you're back posting using another alias and still presenting as this mb's low bar as evidenced by the above exercise in grammatical chaos. damn If I didn't forget how entertaining these back forths with an utter moron could be, go figure.
now that`s a visual that i admit elicits a chuckle. the couldn`t happen to a more deserving person thing comes to mind as well.
dowface/dscorr: androgynous and a moron, life`s gonna come at you sideways for the most part it would seem . if you`re gonna continue speculating in stocks perhaps a Due Diligence class or two may help, you`re gonna need all the help you can get pat.
"And, I don't care what the clinical advances are that they identify."
this statement is an admission of consciously excluding all possibilities relative to the possible success of NAVB`s strategy in the growing of shareholder value/wealth. to consciously exclude all possibilities regardless of the endeavor belies an agenda, in this case a short agenda as expressed by hanovk. the passage of time and a minimal one at that(inmho) will provide the necessary clarity as to the correct speculation. in the mean time the subtle to outright bashes will increase in both frequency and vitriol because of said devolving short agenda as propagated by those individuals with multiple aliases and ZERO integrity. it`s what bashers do, it`s who bashers are...
c`est la vie and my money is on eespelan`s speculation going forward.
spew that is absolutely irrelevant to meaningless. hey dungforbrains, gotta give ya credit though for the way ya oversold yourself relative to the basher thing, suggest you keep your day job as a fluff....
hey, a new fluff in support of obvious bashers, welcome! btw please offer the appropriate grammar/spelling, and conjugations, that is and if ya can break away from the fluff thing....welcome again tool!
nice of ya to supply the springboard pat....who says an androgynous whatever can`t be accomadating? lol!
NAVB / Message Board
Previous Message Post Message Post a Reply return to message board, top of board
Msg 8662 of 8662 at 7/2/2015 8:18:07 AM by moneyonomics
The following message was updated on 7/2/2015 8:33:21 AM.
macrophage-therapeutics-reports-data. and navidea-announces-clinical-data-...investor presentation July 7- from kent on otl--what other details will McGrath present this evening on translational studies???
Navidea Biopharmaceuticals, Inc.. NAVB and its subsidiary, Macrophage Therapeutics, Inc., today announced that imaging results from the Manocept™ clinical trial in Kaposi's Sarcoma (KS) and other preclinical studies were presented at the 18th International Workshop on Kaposi's Sarcoma Herpesvirus (KSHV) and Related Agents in Hollywood, Florida. The clinical imaging study, using Tc 99m tilmanocept, a Manocept platform product, in both HIV+ and HIV- patients suggests that KS tumor lesions, both cutaneous and suspected extra-cutaneous sites, can be easily visualized and mapped, demonstrating that this technique may potentially provide a means for routine patient assessment. The results also show that use of Manocept represents a potential therapeutic pathway for targeting tumor associated macrophages (TAMs). Manocept agents are designed to target CD206, which is highly expressed on TAMs and the KS tumor itself. As a potential therapeutic, Manocept could be used as a precision vehicle to deliver payloads to tumor sites throughout the body.
These pre-clinical and clinical studies support using Kaposi's sarcoma as a model tumor system for evaluating therapeutic approaches for the Manocept platform in other forms of solid tumors," commented Michael Tomblyn, M.D., Navidea's Chief Medical Officer. "They provide evidence that Manocept agents can target CD206 and are internalized into tumor associated macrophages and tumor cells. This along with clinical observations that demonstrate tilmanocept can be used to image KS tumors both externally and internally indicates excellent potential for immunotherapeutic utility.
more coming tonight longs, bashers carry on, lol!!!!!!!!!!!!!!
Reinforces Therapeutic Potential of Targeting Activated Macrophages via the CD206 Receptor-- Data also suggest a new origin of KS as a macrophage fusion tumor -
DUBLIN, Ohio, Jul 02, 2015 (BUSINESS WIRE) -- Navidea Biopharmaceuticals, Inc. (nyse mkt:NAVB) and its subsidiary, Macrophage Therapeutics, Inc., today announced that imaging results from the Manocept™ clinical trial in Kaposi’s Sarcoma (KS) and other preclinical studies were presented at the 18th International Workshop on Kaposi's Sarcoma Herpesvirus (KSHV) and Related Agents in Hollywood, Florida. The clinical imaging study, using Tc 99m tilmanocept, a Manocept platform product, in both HIV+ and HIV- patients suggests that KS tumor lesions, both cutaneous and suspected extra-cutaneous sites, can be easily visualized and mapped, demonstrating that this technique may potentially provide a means for routine patient assessment. The results also show that use of Manocept represents a potential therapeutic pathway for targeting tumor associated macrophages (TAMs). Manocept agents are designed to target CD206, which is highly expressed on TAMs and the KS tumor itself. As a potential therapeutic, Manocept could be used as a precision vehicle to deliver payloads to tumor sites throughout the body.
Navidea Biopharmaceuticals, Inc. (NAVB) Pre-Market Trading
NAVB $1.73* 0.116.79%
*Delayed - data as of 07/02/2015 08:39 - Find a broker to begin trading NAVB now Exchange: AMEX
Industry: Health Care
Community Rating: Bullish
View: NAVB Pre-Market
Jul. 1, 2015 Market Close: $ 1.62 Pre-Market Charts | After Hours Charts
View most recent trades for the selected time period:
Pre-Market Volume: Pre-Market High: Pre-Market Low:
17,632 $ 1.75 $ 1.70
hey dungforbrains: are you at the masengill shooters again? you`re already operating at a deficit, a product of...#$%$ love? the last thing you need is an over abundance of said consumptive....whatever. shut `er down son, you`re inabilities to bash really make ya boring....what`s up with the "threw life" thing? GD, you`re an uneducated fool aren`t ya?
"can see you stumble threw life just guessing like most you wont believe the truth so take a look at palantir 777 fascitis he agrees with me, why are you on this site to begin with you can contribute only very little and half of that is fantasy, so take your nickel and go home."
hey dungforbrains: as you can see via guidance and even using the made up number of cash on hand you provided($8kk), NAVB clearly makes the finish line/BREAKEVEN(Q1-2016) with room to spare. the real number as to cash on hand($23kk) + the credit line($27kk) +guidance revenue for the year($12kk)=$62kk+- actual available cash, no wonder you had to post such an obvious.....miscalculation, lol. ya only missed the cash actual by a multiple of 7.75, I guess a nickel a bash from ya just ain`t worth what it used to be.
hang it up moron while your....ahead? lol!!!!!!!!!!!!!!!!!!!!!!!!!!!!!